Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) was down 4.4% during mid-day trading on Monday . The stock traded as low as $14.33 and last traded at $14.04. Approximately 3,990 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 6,628 shares. The stock had previously closed at $14.68.
Pharming Group Stock Up 5.0%
The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79. The firm has a market capitalization of $1.00 billion, a PE ratio of -112.31 and a beta of 0.05. The company's 50 day simple moving average is $12.23 and its 200-day simple moving average is $10.45.
Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.16. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The business had revenue of $93.20 million for the quarter, compared to analysts' expectations of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. On average, analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current fiscal year.
Hedge Funds Weigh In On Pharming Group
An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,979 shares of the company's stock, valued at approximately $32,000. 0.03% of the stock is currently owned by institutional investors and hedge funds.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
